Dotti Patch, Extended Release
Product Images NDC 72162-2034

Product Visual Gallery

This gallery contains 17 technical images submitted to the FDA as part of the official labeling for Dotti (NDC 72162-2034). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

1 (Dotti Estradiol Transdermal System 1)

Chemical structure diagram of estradiol showing the arrangement of its carbon rings and functional groups including hydroxyl (OH) groups. The schematic includes standard organic chemistry notation with hydrogen atoms and methyl groups depicted.*

FDA Label Image

4a (Dotti Estradiol Transdermal System 10)

An instructional illustration showing a person peeling the backing off a rectangular adhesive transdermal patch, preparing it for application to the skin.*

FDA Label Image

4b (Dotti Estradiol Transdermal System 11)

An instructional line drawing showing two hands peeling apart a DOTTI estradiol transdermal patch. The illustration demonstrates how to remove the protective liner to expose the adhesive side of the patch for application.*

FDA Label Image

4c (Dotti Estradiol Transdermal System 12)

An instructional line drawing showing a hand holding a small circular transdermal patch near a person's abdomen, illustrating placement or application of the patch product.*

FDA Label Image

4d (Dotti Estradiol Transdermal System 13)

An instructional illustration demonstrating the application of a transdermal patch. The image shows hands placing a small patch onto the skin, indicating the correct method for applying the DOTTI estradiol extended-release patch.*

FDA Label Image

4e (Dotti Estradiol Transdermal System 14)

An instructional illustration showing hands applying a DOTTI estradiol transdermal patch to the lower abdominal area. The diagram demonstrates proper placement of the patch on the skin for extended-release hormone delivery.*

FDA Label Image

4f (Dotti Estradiol Transdermal System 15)

Illustration showing the application of a transdermal patch on the skin of the wrist or forearm area. The image depicts a hand holding or placing the patch on the skin.*

FDA Label Image

4g (Dotti Estradiol Transdermal System 16)

An instructional illustration showing a hand applying a small round transdermal patch to the lower abdominal area of the body. This diagram is related to the application of the DOTTI estradiol extended-release patch.*

FDA Label Image

2 (Dotti Estradiol Transdermal System 2)

Illustration depicting the three layers of a DOTTI estradiol transdermal patch: (1) Backing layer, (2) Adhesive layer containing estradiol, and (3) Protective liner.*

FDA Label Image

Figure 1 (Dotti Estradiol Transdermal System 3)

A line graph depicting plasma concentration of estradiol over time (days) for four different dosages: 0.1 mg/day, 0.075 mg/day, 0.05 mg/day, and 0.0375 mg/day. The y-axis shows concentration in pg/mL ranging approximately from 0 to 160, and the x-axis shows time up to 4 days. Each dosage is represented by a distinct marker and line trend showing plasma level changes over time.*

FDA Label Image

2 (Dotti Estradiol Transdermal System 4)

A bar chart comparing mean reductions from baseline over 4, 8, and 12 weeks between Estradiol 0.0375 mg/day and placebo groups. The x-axis shows the time points (Week 4, Week 8, Week 12), and the y-axis presents mean reduction from baseline. Bars indicate greater reduction for Estradiol compared to placebo at all time points, with sample sizes and standard deviations noted.*

FDA Label Image

2 (Dotti Estradiol Transdermal System 5)

A line graph depicting percentage change from baseline over treatment duration in weeks (26, 52, 78, 104) for different dosages of Estradiol (0.1 mg/day, 0.05 mg/day, 0.0375 mg/day, 0.025 mg/day) and placebo. The graph presents trends of the response to these dosages compared to placebo over time.*

FDA Label Image

1 (Dotti Estradiol Transdermal System 6)

A line graph showing percent change from baseline over treatment duration in weeks (26, 52, 78, 104) for different dosages of estradiol (0.1 mg/day, 0.05 mg/day, 0.0375 mg/day, 0.025 mg/day) compared to placebo. Higher estradiol doses show increased percent change over time, with statistical significance indicated against placebo at various points.*

FDA Label Image

1 (Dotti Estradiol Transdermal System 7)

A usage instruction panel for DOTTI, an estradiol transdermal system. It includes a checklist for patch change days with pairs of weekdays: Sun/Wed, Mon/Thu, Tue/Fri, Wed/Sat, Thu/Sun, Fri/Mon, and Sat/Tue. The panel guides users on which two days to change the patch.*

FDA Label Image

2 (Dotti Estradiol Transdermal System 8)

An instructional illustration showing the application of a DOTTI estradiol transdermal patch. It depicts a hand placing the circular patch onto the skin of the abdomen, demonstrating proper placement for the 0.05 mg/day extended-release dosage form.*

FDA Label Image

3 (Dotti Estradiol Transdermal System 9)

Packaging label for DOTTI estradiol transdermal patch, extended release, 0.05 mg/day strength. The label features a simple design showing the outline of the patch. The product is labeled by Bryant Ranch Prepack with NDC 72162-2034.*

FDA Label Image

Label (Lbl721622034)

DOTTI 0.05 mg/day estradiol transdermal system extended-release patch packaging label. The label indicates the product delivers 0.05 mg/day of estradiol and comes in a package of 8 systems. It is relabeled by Bryant Ranch Prepack and manufactured by Amneal Pharmaceuticals, LLC. Storage and usage instructions are also included on the label.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.